Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16196716 | 0.82 | CHRNB2 (0.43) | CHRNB2CHRNA4USP2ALDH1A1TP53 | |
| SCHEMBL188568 | 0.80 | CHRNB2 (0.49) | CHRNB2CHRNA4 | |
| SCHEMBL19668758 | 0.78 | CHRNB2 (0.46) | CHRNB2CHRNA4 | |
| SCHEMBL188863 | 0.77 | CHRNB2 (0.47) | CHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL12179763 | 0.77 | CHRNB2 (0.47) | CHRNB2CHRNA4 | |
| SCHEMBL26923027 | 0.76 | CHRNB2 (0.45) | CHRNB2CHRNA4 | |
| SCHEMBL7102411 | 0.76 | CHRNB2 (0.47) | CHRNB2CHRNA4 | |
| SCHEMBL428322 | 0.76 | CHRNB2 (0.49) | CHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL7924171 | 0.76 | MAPT (0.47) | CHRNB2CHRNA4 | |
| SCHEMBL30174297 | 0.76 | CHRNB2 (0.49) | CHRNB2CHRNA4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107108587-B | Aldosterone synthase inhibitors | 勃林格殷格翰国际有限公司 | 2020-05-22 | — | — | CN | disclosed |
| US-9745289-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| EP-3207039-A1 | ALDOSTERONE SYNTHASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2017-08-23 | — | — | EP | disclosed |
| WO-2016061161-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-21 | — | — | WO | disclosed |
| US-20160108026-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108026-A1 | ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, HSD11B1 | CHRNB2 3601/4885CHRNA4 4219/4885USP2 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.